Checkpoint Therapeutics (CKPT) Stock Price, News & Analysis

Company Overview

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Key Stats

• Today's Range: $3.33 to $3.76
• 50-Day Range: $2.54 to $4.39
• 52-Week Range: $1.38 to $4.50
• Volume: 2.23 million shs
• Average Volume: 675,598 shs
• Market Capitalization: $183.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Buy

Checkpoint Therapeutics Stock Analysis - MarketRank™

Checkpoint Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 242nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Checkpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Checkpoint Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Checkpoint Therapeutics are expected to grow in the coming year, from ($0.91) to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Checkpoint Therapeutics is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Checkpoint Therapeutics is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.19% of the float of Checkpoint Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Checkpoint Therapeutics has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Checkpoint Therapeutics has recently increased by 8.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Checkpoint Therapeutics does not currently pay a dividend.

Dividend Growth

Checkpoint Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.63

Percentage of Shares Shorted

16.19% of the float of Checkpoint Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Checkpoint Therapeutics has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Checkpoint Therapeutics has recently increased by 8.96%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.68

News Sentiment

Checkpoint Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Checkpoint Therapeutics this week, compared to 3 articles on an average week.

Search Interest

24 people have searched for CKPT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

15 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Checkpoint Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,820,790.00 in company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Checkpoint Therapeutics is held by insiders.

Percentage Held by Institutions

Only 22.00% of the stock of Checkpoint Therapeutics is held by institutions.

CKPT Stock Analysis - Frequently Asked Questions

How have CKPT shares performed this year?

Checkpoint Therapeutics' stock was trading at $2.29 at the beginning of the year. Since then, CKPT stock has increased by 63.8% and is now trading at $3.75.
View the best growth stocks for 2024 here.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.08.

When did Checkpoint Therapeutics' stock split?

Checkpoint Therapeutics shares reverse split before market open on Sunday, December 4th 2022. The 1-10 reverse split was announced on Sunday, December 4th 2022. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 4th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Checkpoint Therapeutics' major shareholders?

Top institutional investors of Checkpoint Therapeutics include Geode Capital Management LLC (0.95%), PVG Asset Management Corp (0.31%), Wealth Enhancement Advisory Services LLC (0.36%) and State Street Corp (0.21%). Insiders that own company stock include James F Oliviero III and William Garrett Gray.
View institutional ownership trends.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Checkpoint Therapeutics investors own include TG Therapeutics (TGTX), Bionano Genomics (BNGO), Fortress Biotech (FBIO), NIO (NIO), uniQure (QURE), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CKPT
• CUSIP: N/A
• CIK: 1651407
• Web: www.checkpointtx.com
• Phone: (781) 652-4500
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.50
• High Stock Price Target: $20.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +260.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-51,850,000.00
• Net Margins: N/A
• Pretax Margin: -98,868.08%
• Return on Equity: N/A
• Return on Assets: -659.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.29
• Quick Ratio: 0.29

Sales & Book Value

• Annual Sales: $47,000.00
• Price / Sales: 3,896.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.47) per share
• Price / Book: -7.98

Miscellaneous

• Outstanding Shares: 48,833,000
• Free Float: 47,808,000
• Market Cap: $183.12 million
• Optionable: Optionable
• Beta: 1.34